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ABSTRACT  A 49-year-old Japanese man visited our institution for the treatment of metastatic 
rectal cancer. He had no history of interstitial pneumonia or smoking. Although he achieved 
partial remission with combination chemotherapy consisting of 5-fluorouracil, leucovorin, and 
oxaliplatin plus bevacizumab, this regimen failed after 46 courses. A salvage chemotherapy 
consisting of 5-fluorouracil, leucovorin, and irinotecan plus panitumumab was initiated. However, 
6 days after treatment initiation, asymptomatic hypoxia was detected. Chest computed 
tomography revealed interstitial lung disease; therefore, chemotherapy was discontinued and 
corticosteroid pulse therapy was immediately started. Chest computed tomography on day 20 
of the salvage chemotherapy revealed progressive interstitial lesions with lung volume loss 
and mediastinal emphysema. He passed away a few days later because of respiratory failure. 
In conclusion, physicians should be aware of the adverse event wherein administration of 
chemotherapy containing an anti-epidermal growth factor receptor monoclonal antibody might 
result in a fatal outcome. (Accepted on December 4, 2012)
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INTRODUCTION
   Most anti-neoplastic drugs have the potential to 
induce pulmonary toxicity in the lung parenchyma, 
airways, pleura, and pulmonary circulation. The 
mainstay of treatment of drug-induced pneumonia 
is to first identify and eliminate the causative agent 
as soon as possible１）. Anti-epidermal growth factor 
receptor (EGFR) monoclonal antibodies, cetuximab 
and panitumumab, are effective drugs for treating 
colorectal cancer (CRC) by competitively binding 
to the accessible extracellular domain of EGFR and 
inhibiting dimerization and subsequently, tumor 
growth and metastasis２）; however, they rarely induce 
interstitial lung disease (ILD). Only a few case reports 
have warned that anti-EGFR monoclonal antibody 
might potentially induce ILD in the treatment of a 
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variety of malignancies, including CRC. Here we 
report a case of panitumumab-induced fatal ILD with 
a literature review. 
CASE REPORT
   A 49-year-old Japanese man visited our institution 
for the treatment of metastatic rectal cancer. 
He had no history of interstitial pneumonia or 
smoking and had been diagnosed with advanced 
rectal cancer 4 years earlier. He underwent low 
anterior resection and opted to receive adjuvant 
chemotherapy consisting of 5-fluorouracil (5-FU) 
and leucovorin (LV) for 6 months. Unfortunately, 
he was readmitted to our hospital 5 months later, 
because chest computed tomography (CT) revealed 
a recurrence with multiple lung metastases. A 
combination chemotherapy consisting of 5-FU, 
LV, and oxaliplatin (FOLFOX) plus bevacizumab 
was initiated and achieved a partial response. 
However, this regimen failed after 46 courses. 
Because his performance status was well preserved, 
a salvage chemotherapy consisting of 5-FU, LV, 
and irinotecan (FOLFIRI) plus panitumumab 
was initiated. Six days after the treatment began, 
asymptomatic hypoxia was indicated. Chest X-ray 
and CT on day 11 of the salvage chemotherapy 
revealed interstitial pneumonia with multiple lung 
nodules (Fig. 1A and B). Differential diagnoses such 
as lymphangitis carcinomatosa, cardiac heart failure, 
and pulmonary infection were considered from the 
radiological findings, laboratory data, and negative 
sputum cultures; however, the patient's surfactant 
protein-D (226.6 ng/ml) and KL-6 (981 U/ml) 
levels were elevated, which is characteristic of ILD, 
and he was diagnosed with drug-induced ILD. The 
chemotherapy was discontinued and oral prednisone 
pulse therapy (70  mg/day) was immediately 
in i t i a ted .  Ches t  CT on  day  20  o f  sa lvage 
chemotherapy revealed progressive interstitial 
lesions with lung volume loss and mediastinal 
emphysema (Fig. 2). Although he received intensive 
therapy with mandatory ventilation, he passed away 
a few days later. No autopsy was performed.
DISCUSSION
   Anti-EGFR therapies demonstrate certain activities 
in the treatment of CRC. Anti-EGFR monoclonal 
antibodies bind to the extracellular domain of EGFR 
Fig. 1   Chest X-ray (A) and computed tomography (B) on day 11 of panitumumab-containing chemotherapy revealed bilateral 
patchy ground glass opacities and nodular lesions.
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preventing ligand binding and interrupting signal 
transduction. Phase II and III trials in patients with 
previously treated or untreated metastatic CRC, 
especially K-Ras wild type CRC, demonstrated 
antitumor activity of the anti-EGFR monoclonal 
antibody as a single agent or in combination with 
irinotecan- or oxaliplatin-based chemotherapies３，４）. 
Moreover, the antibodies might cause severe non-
hematological toxicities. A Japanese post-marketing 
surveillance of cetuximab in 2126 patients with 
metastatic CRC revealed that 21.5% experienced 
adverse drug reactions greater than grade 3５）. 
While skin and gastrointestinal disorders were 
frequently observed, ILDs were observed in 1.2% 
of patients (n = 24) and ILDs more than grade 3 
were reported in 0.7% of patients ( n = 15 ). The 
outcomes included recovery in 2 patients, lower 
severity in 6 patients, non-recovery in 5 patients, 
death in 10 patients, and unknown in 1 patient. 
This report indicated that approximately 40-60% 
of Japanese patients with cetuximab-induced ILD 
had poor prognoses. In their study, Kang et al.６） 
determined the incidence and clinical characteristics 
of adverse pulmonary reactions in patients treated 
with anticancer chemotherapy including monoclonal 
antibodies. They performed a retrospective cohort 
study that included patients who were treated with 
chemotherapy including rituximab, trastuzumab, 
cetuximab, or bevacizumab. In total, 1078 patients 
were included (418, 329, 122, and 209 were treated 
with rituximab, trastuzumab, cetuximab, and 
bevacizumab, respectively). Adverse pulmonary 
reactions were identified in 36 patients (3.5%) and 
the incidence differed among agents: cetuximab 
(9%), rituximab (5.3%), trastuzumab (0.6%), 
and bevacizumab (0.5%). In cases treated with 
cetuximab (n = 122), no patients experienced drug-
induced ILD. ILD due to anti-EGFR monoclonal 
antibody has rarely been reported, unlike selective 
inhibitors of the EGFR tyrosine kinase domain７）. 
Inhibition of EGFR signal transduction can induce 
fatal ILD in spite of different action mechanisms. 
We summarized the cases of severe ILD due to anti-
EGFR monoclonal antibody８－11） in Table 1. Three 
cases among the 5 in the English medical literature, 
including the present case, resulted in fatal outcomes 
Fig. 2    Chest computed tomography on day 20  of 
panitumumab-containing chemotherapy revealed progressive 
interstitial lesions with lung volume loss and mediastinal 
emphysema.
Table 1. Cases of severe ILD caused by chemotherapy including anti-EGFR monoclonal antibody
AuthorRef Age/Sex Disease Regimen Time from initiation of 
chemotherapy to onset 
of ILD
Outcome
Chua W（７） 78/M Rectum CPT-11/C-mab 60 days Recovered
Shibahara H（８） 60/M Colon CPT-11/C-mab 147 days Dead
Lai JH（９） 69/M Colon FOLFOX/C-mab 101 days Dead
Yamamoto K（10） 58/M Colon FOLFIRI/P-mab 15 days Recovered
Present case 49/M Rectum FOLFIRI/P-mab 6 days Dead
C-mab: cetuximab; CPT-11: irinotecan; EGFR: epidermal growth factor receptor; FOLFIRI: 5-fluorouracil, leucovorin, and 
irinotecan; FOLFOX: 5-fluorouracil, leucovorin, and oxaliplatin; ILD: interstitial lung disease; P-mab: panitumumab
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due to ILD, although they were treated with steroid 
pulse therapy. To the best of our knowledge, ILD 
caused by panitumumab-containing chemotherapy 
has been described in two reports, including the 
present case. 
   Preexisting pulmonary fibrosis has been described 
as a risk factor for development of EGFR-TKI 
induced ILD and was likely a significant factor12）. 
In our present case, the patient had the history of 
repeated treatment of oxaliplatin, which had the 
significant potential to cause drug-induced ILD. It 
is possible that minute lung damage by the previous 
chemotherapy might lead to rapid progression of 
ILD by panitumumab-containing chemotherapy.
   Chest CT clearly revealed the mediastinal 
emphysema in our present case. The most probable 
cause of mediastinal emphysema is the rupture of 
the alveolar walls caused by thoracic hyper pressure 
maneuvers, with the consequential escape of air into 
the interstitium and a further centripetal dissection 
along the broncho-vascular sheaths until it reaches 
the mediastinum through the hyllum. Occasionally, 
alveolar rupture can occur during an attack of 
asthma or as the result of a peripheral parenchymal 
affection of interstitial processes that lead to 
honeycombing13）.
   From these findings, we inferred that rapid 
progression of ILD had caused the thoracic 
hyper pressure maneuvers and then mediastinal 
emphysema occurred. 
   In conclusion, our case indicated the need for 
physicians to be aware of the potential for ILD 
development and fatal outcomes in patients being 
treated with chemotherapy containing anti-EGFR 
monoclonal antibody.
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